{
    "Trade/Device Name(s)": [
        "IDS ACTH II"
    ],
    "Submitter Information": "Immunodiagnostic Systems Limited",
    "510(k) Number": "K223867",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060585"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CKG"
    ],
    "Summary Letter Date": "July 21, 2023",
    "Summary Letter Received Date": "July 24, 2023",
    "Submission Date": "August 16, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1025"
    ],
    "Regulation Name(s)": [
        "Adrenocorticotropic Hormone (ACTH) Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Adrenocorticotropic hormone (ACTH)"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2 EDTA tube",
        "K3 EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "IDS-iSYS Multi-Discipline Automated System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence",
        "Sandwich assay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for IDS ACTH II chemiluminescent immunoassay for quantitative determination of ACTH in human EDTA plasma on the IDS-iSYS system",
    "Indications for Use Summary": "Automated in vitro diagnostic assay for quantitative determination of ACTH in human K2 and K3 EDTA plasma on the IDS system, used as an aid in assessing pituitary and adrenal gland function and differential diagnosis of hyper- and hypo-cortisolism",
    "fda_folder": "Clinical Chemistry"
}